CPHI 2024: The Premier Event for the Pharmaceutical Industry is Just Around the Corner

news

The most anticipated pharmaceutical event of the year is fast approaching! CPHI 2024, set to take place in Milan from October 8-10, is the world’s largest pharmaceutical exhibition. This event is a unique convergence of six individual pharma sectors, covering every aspect of the industry—from ingredients and FDF to machinery, packaging, outsourcing, and biopharmaceuticals.

What to Expect at CPHI 2024

This year’s CPHI is shaping up to be bigger and better than ever. Here’s what attendees can look forward to:

  • 62,000 attendees from across the globe
  • 2,400 exhibitors showcasing the latest innovations and services
  • 166 countries represented, making it a truly global gathering
  • 150+ expert speakers sharing insights and trends shaping the future of pharma

For those who have previously attended a CPHI event, you’ll know that it’s tailored specifically for professionals in the pharmaceutical industry. Whether you’re looking to network, learn, or explore new business opportunities, CPHI is the place to be.

Spotlight on Cyclodextrins

Among the myriad of products and technologies on display, cyclodextrins will feature prominently at CPHI 2024. Expect to meet a wide range of users and manufacturers of cyclodextrins, including:

And, of course, CarboHyde will be there too. Our team will be well-represented, with CFO Gergely Toth, COO Tamás Vargadi, and Tamas Sohajda all attending the event. We’re excited about the opportunity to engage with industry peers and discuss potential collaboration on cyclodextrin projects.

Let’s Connect at CPHI 2024

If you’re planning to attend CPHI in Milan, we would love to catch up with you. This event presents a fantastic opportunity to plan and strategize around cyclodextrin-related projects. We believe that face-to-face interactions at such a prestigious event can pave the way for meaningful collaborations.

We look forward to seeing you there!

University of the Witwatersrand and CarboHyde Zrt Announce Strategic Collaboration to Develop Breast Cancer Therapeutic

news,

Johannesburg, South Africa, and Budapest, Hungary – [28/08/2024] – The University of the Witwatersrand (WITS), a leading research institution in South Africa, and CarboHyde Zrt, a pharmaceutical company based in Hungary, have entered into a strategic collaboration to advance the development of a novel breast cancer therapeutic. This partnership aims to accelerate the development of this asset further while securing funding opportunities within Europe and ensuring the successful progress of this promising therapeutic from research to market.

The collaboration between WITS and CarboHyde will be executed in multiple phases: first, finishing the preclinical studies, and later, starting clinical trials together or with other partners.

This collaboration marks a significant milestone in the fight against breast cancer, combining the strengths of two innovative organizations across continents. By pooling their resources, expertise, and networks, WITS and CarboHyde aim to bring this cutting-edge therapeutic to market, benefiting patients and healthcare systems worldwide.

For more information, please contact CarboHyde at info@carbohyde.com

About the University of the Witwatersrand: The University of the Witwatersrand (WITS) is a leading research-intensive institution based in Johannesburg, South Africa. WITS is dedicated to advancing knowledge through impactful research and is recognized globally for its contributions to science and innovation.

About CarboHyde Zrt: CarboHyde is a pharmaceutical company based in Budapest, Hungary, specializing in carbohydrate chemistry, including cyclodextrins. CarboHyde focuses on creating innovative solutions and collaborating with partners worldwide to bring breakthrough technologies to market in the pharmaceutical arena.

Preparing for a busy September

news

Full team

Unbelievable, but it has been 191 days since we had the full CarboHyde team together in person.

After completing 3 Bicyclos HEurope secondments, now we will enjoy a few months together before we depart again in the fall.

Now that Kristof is back too, he focuses on finishing his PhD and just tackled his practical defence.

CarboHyde team

Roquette – CarboHyde webinar vol 3

Our next free webinar, titled “Cyclodextrin formulations: The Journey from the Benchtop to the Patients” brings together experts who will guide us through the milestones of this remarkable journey.

Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from laboratory research to real-world patient care. Our esteemed speakers will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.

Link for registration: https://www.congress-service.hu/rendezveny/cyclodextrinwebinar2024

Time&Date: September 26., 2024, 3 pm – 5 pm (CEST, Budapest time)

Cyclodextrin Workshop

We still have a few seats open for this fantastic event we are organizing together with Eötvös Loránd University under the frame of the Bicyclos HEurope project.

A 2,5-day workshop in September 2024 in the lovely Budapest, dealing with New approaches to sustainable synthetic chemistry of carbohydrates and derivatives.

Our target audience are undergrad and PhD students, yet industry professionals and any carbohydrate/cyclodextrin beginners are more than welcome. Learn more about the event: https://lnkd.in/gbHUg-DX

Register: https://lnkd.in/dZsis8UW

It will be stunning!

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses

Egyéb kategória

Scientists create first mouse model with complete, functional human immunesystem and a human-like gutmicrobiome that is capable of mounting specific antibody responses.

Such a model would have unlimited uses in pharma development. The work of Paolo Casali et al groundbreaking and will disrupt the animal models we use for efficacy and safety studies. How would you use this model first? I imagine studies with vaccines probably…

Nature Immunology, 5 July 2024

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses | Nature Immunology

Carbohyde blog

Cyclodextrin derivatives for the treatment of gout and hyperuricemia

Egyéb kategória

Inspiring research and patent from our collaborators at Università degli Studi di Torino and Universidad de Murcia

Adrián Matencio Durán, Francesco Trotta, Yousef Khazaei Monfared, Fabrizio Caldera, and José Manuel López Nicolás disclosed an invention in which various cyclodextrins are investigated in the therapy of gout and hyperuricemia.

WO2024133757 CYCLODEXTRIN DERIVATIVES FOR THE TREATMENT OF GOUT AND HYPERURICEMIA (wipo.int)

Cyclodextrin formulations: The Journey from the Benchtop to the Patients

news,

Our next free webinar, titled “Cyclodextrin formulations: The Journey from the Benchtop to the Patients” brings together experts who will guide us through the milestones of this remarkable journey.

CArboHyde, webinar, Roquette

Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from laboratory research to real-world patient care. Our esteemed speakers will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.

Link for registration: https://www.congress-service.hu/rendezveny/cyclodextrinwebinar2024

Time&Date: September 26., 2024, 3 pm – 5 pm (CEST, Budapest time)

Agenda:

  1. Preparation of Parenteral and Oral Cyclodextrin-Based Formulations and Their Physical CharacterizationSpeaker: Dr. Carmen Popescu (Roquette) – Dr. Popescu will unveil the meticulous process of formulating cyclodextrin-based drugs for parenteral and oral administration. From solubility enhancement to stability studies, discover how cyclodextrins bridge the gap between lab experiments and clinical applications.
  2. Cyclodextrins in Liquid, Transdermal, and Other Non-Traditional FormsSpeaker: Dr. Balazs Kondoros (CarboHyde) – Dr. Kondoros will guide us beyond conventional dosage forms. Explore how cyclodextrins revolutionize liquid formulations, transdermal patches, and other innovative delivery methods. Witness the transition from theoretical concepts to practical solutions.
  3. Hunting for Cyclodextrins: Analytical Assay Methods in Biological FluidsSpeaker: Dr. Tamas Sohajda (Carbohyde) – Dr. Sohajda’s presentation focuses on the detective work involved in studying cyclodextrins within biological matrices. Learn about cutting-edge assay techniques, their role in clinical trials, and the critical insights they provide.
  4. Promising Future for HPBCD in InhalationSpeaker: Dr. Natacha Rocks (Aquilon) – Dr. Rocks will unveil the exciting prospects of hydroxypropyl-β-cyclodextrin (HPBCD) in inhalation therapies. From lung-targeted drug delivery to patient-friendly devices, witness how cyclodextrins are poised to transform respiratory medicine.

Who Should Attend: Researchers, clinicians, pharmaceutical professionals, and anyone curious about the journey of cyclodextrins—from lab discoveries to patient impact.

Don’t miss this opportunity to explore the bridge between science and healing. Register now and join the cyclodextrin revolution!

I would be delighted to hear suggestions for upcoming topics and engage in Q&A, so please feel free to add your impressions in the comments or via email at tamas.sohajda@carbohyde.com. Thank you.

In the coming weeks, we will continue focusing on using cyclodextrins as active ingredients, disease by disease. Stay tuned!

The first secondment at Bicyclos has been completed

news,

Kristóf Felegyi just completed CarboHyde’s very first secondment under the scope of the Bicyclos HEurope project under the strong support of Csenge Anna Felegyi-Tóth.

Kristof worked for 5 months in the lab of Jose Manuel Garcia Fernandez under the supervision of Juanma Benito and created various cyclodextrin polymers that we will evaluate for gene and small molecule delivery.
😎
We appreciate the strong support and hospitality of CSIC and look forward to further collaborations.

As Kristof did not take a single photo in the lab, we can only trust he did not only do sightseeing in the wonderful city

Kristof Felegyi, Bicyclos, CarboHyde, Seville

CarboHyde CEO Tamas Sohajda Presents at CPHI NA on Novel Uses of Cyclodextrins in the Pharmaceutical Industry

news, ,

CarboHyde CEO Tamas Sohajda recently delivered a compelling presentation at the CPHI North America conference, focusing on innovative applications of cyclodextrins in the pharmaceutical industry. His talk highlighted how these unique cyclic oligosaccharides can enhance drug delivery, improve solubility, and stabilize formulations, offering significant benefits to pharmaceutical development.

Cyclodextrins, known for their ability to form inclusion complexes with various molecules, have been extensively studied for their potential to revolutionize drug formulations. Sohajda’s presentation delved into recent advancements and case studies demonstrating the successful integration of cyclodextrins in new drug delivery systems. These developments promise to improve the efficacy and safety of numerous medications, addressing longstanding challenges in drug formulation and bioavailability.

The talk received considerable attention from industry professionals, underscoring CarboHyde’s leading role in pioneering the use of cyclodextrins for pharmaceutical innovation. Attendees had the opportunity to engage with Sohajda, discussing cyclodextrin research’s practical applications and future directions.

A video of the event is available on CPHI website – after a registration – for those who missed the presentation or wish to revisit the insights shared.

CPHI: Lightning Round: Excipients 4.0 – Cyclodextrins (CDs) (video) (cphi-online.com)

On Vimeo:

Dr Tamas Sohajda Lightning Round Excipients 4.0 – Cyclodextrins CDs on Vimeo

Stay tuned for more updates from CarboHyde as they continue to push the boundaries of pharmaceutical technology.